Vicarious Surgical (NYSE:RBOT) & LENSAR (NASDAQ:LNSR) Critical Survey

Vicarious Surgical (NYSE:RBOT) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Vicarious Surgical and LENSAR, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	0	1	0	0	2.00
LENSAR	0	2	0	0	2.00

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 22.27%. LENSAR has a consensus price target of $15.00, suggesting a potential upside of 23.25%. Given LENSAR’s higher probable upside, analysts plainly believe LENSAR is more favorable than Vicarious Surgical.

Profitability

This table compares Vicarious Surgical and LENSAR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-148.14%	-98.07%
LENSAR	-84.49%	-737.30%	-72.60%

Institutional and Insider Ownership

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 12.0% of Vicarious Surgical shares are owned by company insiders. Comparatively, 66.0% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Vicarious Surgical and LENSAR”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22 million	($10.09)	-0.57
LENSAR	$53.49 million	2.72	-$31.40 million	($4.21)	-2.89

LENSAR has higher revenue and earnings than Vicarious Surgical. LENSAR is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vicarious Surgical has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Summary

LENSAR beats Vicarious Surgical on 6 of the 11 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.